Elaborate

Graded B on the mechanism, and the grade describes the mechanism rather than the quality. In a category where nearly every competitor markets agentic AI, Elaborate states plainly that its Protocol Intelligence technology uses patient clinical data to power RULES BASED PROTOCOLS across more than thirty ambulatory specialties. That is a deliberate architectural choice with real advantages: rules anchored to clinician authored protocols are auditable, reproducible and structurally resistant to the drift that learned systems exhibit, the same property that earns Nym Health credit in autonomous coding. Message classification and summarisation are model tasks and are genuinely part of the product, which is why this is B rather than C. Held below A because the rules layer, not a model, is what carries the clinical logic. One inconsistency for a buyer to resolve: customer facing case studies are titled around AI by Elaborate while the technology page describes rules, so ask which components are learned and which are authored. This record credits the plain statement, which puts Elaborate alongside Candid Health and Schrodinger on this index's honest non inflation roster.

The strongest oversight position in this category, and one published derivation away from A. Three things support it. The logic is clinician authored: protocols are built and customised with practising physicians and are configurable per organisation, so the health system rather than the vendor defines what a patient is told. The rules based architecture means a disputed output can be traced to the rule that produced it, which learned systems in this category cannot offer. And Elaborate publishes a 94 percent clinical alignment figure from its Cedars-Sinai partnership, which unlike the time saved metrics that dominate this category is an agreement measure and therefore implies a 6 percent disagreement rate the company has chosen to leave visible. What is missing is the derivation. No definition of clinical alignment, no denominator, no cohort, no adjudication method and no statement of who judged alignment are published. This index's standing lesson from Pieces applies directly: a quantified rate is only as good as its published derivation, and publishing a number invites the question that never publishing one avoids. Also load bearing: result summaries go to the patient AT DIRECT RELEASE, so the message reaches the patient on the Cures Act clock rather than after a clinician reads it.

Better than every peer assessed in this category, and the reason is simple: Elaborate names its mechanism. Protocol Intelligence is described as rules based protocols spanning more than thirty ambulatory specialties, driven by patient clinical data, rather than as undifferentiated agentic AI. Naming the mechanism is what this axis measures, and almost nothing else in this lane does it. Held at B rather than A because there is still no model card, no named model or provider for the classification and summarisation components, no published evaluation methodology, and no statement of the boundary between authored rules and learned components.

The best evidenced record in this category and still short of independent validation. The named customer set is materially larger than any peer: Cedars-Sinai under a stated strategic partnership, Community Health Network, Austin Regional Clinic, Millennium and others, each carrying an attributed outcome figure with a linked write up rather than an anonymous testimonial. Published results include 36 percent less inbox time at ARC, 30 percent less pyjama time at Community Health Network and 94 percent clinical alignment at Cedars-Sinai. The clinical advisory board is named with verifiable credentials including a former executive vice president and chief information officer at Kaiser Permanente and a former chief information officer at Cambridge Health Alliance. Two counterweights keep this at B. No peer reviewed publication or third party evaluation was located, and no methodology, denominator or baseline period accompanies any of the three headline figures. And there are disclosed overlaps a reader should hold in view: one clinical advisor is also chief medical officer at ARC, the customer whose 36 percent figure is cited, and another advisor appears as an investor in the company's seed round announcement. That is common in health technology and it is not an accusation, but it means the advisory board is not an independent check in the way an external evaluation would be, the same caveat this index records for CodaMetrix.

The disclosure surface is real rather than nominal, which by itself separates Elaborate from most of this category. The company runs a public trust centre on Vanta at trust.elaborate.com, openable without contacting sales, and maintains a distinct privacy policy and terms of use rather than a single template page. Elaborate also operates a patient facing portal, so it holds patient accounts directly and is not purely a clinician side integration, which widens the surface a buyer must review. Not established in public materials: whether customer clinical data is used to train or improve any component, what retention applies to results and message content, and what de identification is performed. Graded B for maintaining a verifiable disclosure surface, held below A pending explicit commitments on training use and retention.

HIPAA compliance is asserted with a compliance badge on the home page and the company sells to health systems that would require an executed business associate agreement. No BAA is published, no terms are described, and nothing states whether one is included or separately negotiated. Middle rung of this index's HIPAA ladder. Given Elaborate operates a patient portal in addition to its EHR integration, a buyer should establish which entity holds the patient relationship and which agreement governs data in the portal specifically.

The best security disclosure posture assessed in this category so far. Elaborate runs a live public trust centre hosted on Vanta at trust.elaborate.com, reachable from the site footer and openable without a sales conversation, and displays HIPAA and SOC 2 marks on the home page. A self serve trust centre is the artifact this index looks for, and it is the same platform and posture that distinguished Abstractive Health in the summarisation category. Held at B rather than A on two points: the marketing site does not state whether the SOC 2 is Type I or Type II, which is the question this index asks of every SOC 2 claim, and no other certification such as HITRUST or ISO 27001 is named in publicly rendered materials. Distribution through the Epic Showroom implies Elaborate has passed Epic's own partner review, which is a meaningful third party gate even though its criteria are not public.

No clearance, no submission and no published regulatory analysis. The scoping question this index asks of the whole category applies here in an unusual form. Elaborate does not primarily decide what a clinician sees; it decides what the PATIENT is told about a result, at direct release, before a clinician has necessarily read it. The rules based architecture is the strongest available argument that this falls within the software functions excluded from device regulation under the 21st Century Cures Act, since a clinician can in principle review the protocol that generated any given message. That argument is available but Elaborate has not made it publicly, and a buyer should ask for the documented position rather than infer it. Note the regulatory symmetry worth recording: the same statute that created this company's market by mandating immediate result release is the statute whose device exclusions determine how its product is regulated.

No fairness, subgroup or performance variation disclosure was located, and the exposure here is specific rather than generic. Elaborate generates patient facing explanatory text at scale across more than thirty specialties, and comprehension of that text will vary with health literacy, language and education. A protocol driven explanation that reassures one population may not land the same way in another, and no reading level, language coverage or subgroup comprehension data is published. Separately, and to be recorded neutrally: the product's described value includes helping patients schedule a billable follow up visit where clinically indicated, and the company publishes a return on investment calculator. A results message that both explains a finding and drives a follow up appointment carries an incentive a buyer should see stated, even though converting an anxious call into an appropriate visit is a legitimate clinical outcome. Establish whether any protocol is tuned toward appointment conversion.

The deepest integration position in this category by a clear margin, and the only vendor here reaching Epic. Elaborate is listed in the EPIC SHOWROOM and on the athenahealth Marketplace, which are the two official distribution channels that matter for ambulatory inbox tooling, and it operates natively inside the EMR rather than as a parallel application. The company has separately described integration across more than sixty five electronic medical record systems. Epic distribution is the decisive fact: Epic's In Basket is where the majority of United States ambulatory message volume actually sits, and every other vendor assessed in this category so far names athenahealth alone. Buyers should still confirm which specific workflows are live on their own EHR version rather than assuming the full four module platform ships everywhere.

Cloud delivered with native EMR integration and a separate patient portal. No hosting provider, region, data residency commitment, tenancy model or on premise option is stated in publicly rendered materials. The trust centre may hold some of this detail behind its interactive interface; nothing was retrievable from the public page itself. For a product operating inside academic medical centre environments, residency and tenancy are standard security review questions and a buyer should expect documented answers.

No price is published at any tier and every commercial path routes through a booked demo. No pricing unit is stated, so a buyer cannot tell whether the platform is licensed per provider, per message, per result, per module or per enterprise, and the four module structure makes that ambiguity consequential. Partial credit where it is due: Elaborate publishes a return on investment calculator, which is more than most of this category offers and at least gives a buyer a structured way to model benefit. But a calculator that models return while withholding the cost input leaves the buyer estimating one side of the ratio, and the same asymmetry appears across this category.

The broadest coverage in this category and the only record here evidenced across genuinely different organisation types. Protocols span more than thirty ambulatory specialties, and named deployments cover an academic medical centre (Cedars-Sinai), a community health network (Community Health Network), a large independent multispecialty group (Austin Regional Clinic) and specialty practice. Distribution through both the Epic Showroom and the athenahealth Marketplace means the product is reachable by both enterprise health systems and independent groups, where peers in this category are effectively athenahealth only. The scope is explicitly AMBULATORY: no inpatient, emergency department or inpatient discharge inbox coverage is claimed, and a buyer running a hospital based message queue should treat this as out of scope.